Palopegteriparatide
帕罗培特立帕肽
Report date: 2026/04/23 20:00:25
NME
Base Information
Drug NamePalopegteriparatide
Drug Alias Name +[9]
Classification
Mechanisms of Action
Targets
Therapy Area/Indications
Global Approved Indications
Approved Indications in ChinaN/A
Original Approved Country/Territory
Original Approved Date2023/11/17
Country/Territory +[11]
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesAscendis Pharma
China Registration ClassN/A
Develop Information
Active CompaniesVisen Pharmaceuticals (Shanghai) Co LtdAscendis Pharma Bone Diseases AsAscendis Pharma +[7]
Inactive CompaniesN/A
Active Indications
Inactive Indications